Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
Randomization to the fulvestrant arm (Arm 2) and the anastrozole + fulvestrant arm (Arm 3) will be closed to new patient accrual on 11/01/2018; accrual to these two arms has been met per protocol. Beginning on 11/01/2018 all new patients registered to A011106 will be registered to the anastrozole arm (Arm 1).